| Nov 21 |
GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
|
| Nov 15 |
GRI Bio reports 9M results
|
| Nov 14 |
GRI Bio files to sell 1.58M shares of common stock for holders
|
| Nov 14 |
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
|
| Oct 24 |
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
|
| Oct 21 |
GRI Bio Announces Exercise of Warrants
|
| Oct 16 |
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
|
| Oct 7 |
GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
|
| Sep 30 |
GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
|
| Sep 26 |
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia
|
